Timothy A. Springer
Known title: DirectorCIK: 0001055624
Timothy A. Springer's purchase track record
How the stock did after each of Timothy A. Springer's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
16
of 16 since December 9, 2021
Stock higher 6 months later
6%
3 months: 56%
Median 6-month return
-30.6%
3 months: +12.9%
Beat the S&P 500
6%
median -35.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/9/2025 | RNAC | $1.52M | +21.2% | -10.0% | +23.8% |
| 4/7/2025 | TECX | $10.85M | +33.8% | -2.1% | +33.1% |
| 3/18/2025 | RNAC | $1.37M | -33.0% | -34.3% | +17.7% |
| 2/5/2025 | TECX | $40.00M | -59.5% | -50.5% | +4.7% |
| 1/13/2025 | RNAC | $366K | -29.1% | -28.7% | +7.4% |
| 12/19/2024 | RNAC | $965K | -17.3% | -49.4% | +1.7% |
| 11/14/2024 | RNAC | $7.37M | +11.8% | -38.7% | -0.5% |
| 10/22/2024 | TECX | $10.08M | +14.0% | -46.3% | -9.6% |
| 10/2/2024 | RNAC | $4.29M | -5.9% | -28.0% | -0.7% |
| 9/26/2024 | TECX | $1.44M | +79.1% | -33.8% | -0.9% |
| 8/12/2024 | RNAC | $102K | +55.8% | +45.8% | +13.5% |
| 3/18/2024 | RNAC | $12K | +23.0% | -15.6% | +9.4% |
| 3/8/2024 | RNAC | $675K | +90.5% | -32.4% | +5.6% |
| 2/6/2024 | RNAC | $2K | +14.2% | -27.0% | +5.8% |
| 1/17/2024 | RNAC | $552 | -14.3% | -14.7% | +17.9% |
| 12/9/2021 | RNAC | $12.32M | -42.2% | -59.4% | -13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.
Transaction History
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2026 | View on chart |
| RNAC | ▲ Buy | Open Market | 6,412 | $69K | 4/11/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 36,338 | $391K | 4/11/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 9,478 | $155K | 4/11/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 53,706 | $876K | 4/11/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 8,092 | $135K | 4/10/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 7,966 | $83K | 4/10/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 609 | $7K | 4/10/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 45,144 | $471K | 4/10/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 3,451 | $38K | 4/10/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 45,858 | $767K | 4/10/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 2,861 | $42K | 4/9/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 857 | $13K | 4/9/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 7,342 | $69K | 4/9/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 31 | $308 | 4/9/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 178 | $2K | 4/9/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 16,215 | $237K | 4/9/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 4,856 | $74K | 4/9/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 41,604 | $392K | 4/9/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 87,500 | $1.5M | 4/7/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 412,500 | $7.1M | 4/7/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 54,889 | $856K | 3/20/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 20,234 | $303K | 3/19/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 14,740 | $213K | 3/18/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 660,000 | $33.0M | 2/5/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 129,294 | $7.0M | 2/5/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 4,022 | $72K | 1/14/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 7,962 | $134K | 1/13/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 8,983 | $160K | 1/13/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2025 | View on chart |
| RNAC | ▲ Buy | Open Market | 5,181 | $98K | 12/23/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 21,800 | $413K | 12/20/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 10,529 | $193K | 12/19/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 3,376 | $64K | 12/19/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 11,303 | $197K | 12/19/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 38,114 | $684K | 11/18/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 20,181 | $372K | 11/18/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 277,246 | $4.7M | 11/15/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 74,157 | $1.2M | 11/14/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 22,242 | $377K | 11/14/2024 | View on chart |
| TECX | ▲ Buy | Open Market | 300,000 | $10.1M | 10/22/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 48,880 | $1.1M | 10/4/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 16,650 | $392K | 10/4/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 4,879 | $117K | 10/4/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 9,892 | $211K | 10/4/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 21,278 | $451K | 10/3/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 29,847 | $545K | 10/3/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 10,249 | $195K | 10/3/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 50,489 | $1.0M | 10/3/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 8,043 | $176K | 10/3/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 5,514 | $96K | 10/2/2024 | View on chart |
| RNAC | ▼ Sell | Other | 1,801,314 | — | 10/2/2024 | View on chart |
| RNAC | ▼ Sell | Other | 317,879 | — | 10/2/2024 | View on chart |
| RNAC | ▼ Sell | Other | 2,119,193 | — | 10/2/2024 | View on chart |
| TECX | ▲ Buy | Open Market | 24,531 | $691K | 9/26/2024 | View on chart |
| TECX | ▲ Buy | Open Market | 18,999 | $553K | 9/26/2024 | View on chart |
| TECX | ▲ Buy | Open Market | 4,070 | $123K | 9/26/2024 | View on chart |
| TECX | ▲ Buy | Open Market | 2,400 | $74K | 9/26/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 721,361 | — | 9/25/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 1,307 | — | 9/25/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 1,307 | — | 9/25/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 1,636,832 | — | 9/25/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 1,636,832 | — | 9/25/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 721,361 | — | 9/25/2024 | View on chart |
| TECX | ▼ Sell | Other | 1,054,759 | $0 | 9/24/2024 | View on chart |
| TECX | ▼ Sell | Other | 1,240,893 | $0 | 9/24/2024 | View on chart |
| TECX | ▼ Sell | Other | 186,134 | $0 | 9/24/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 8,016 | $102K | 8/12/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 1,307 | $26K | 7/2/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 1,636,832 | $32.7M | 7/2/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 721,361 | $14.4M | 7/2/2024 | View on chart |
| TECX | ▲ Buy | Grant | 1,551,116 | — | 6/20/2024 | View on chart |
| TECX | ▲ Buy | Grant | 2,692,005 | — | 6/20/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 123,925 | — | 4/8/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 826,169 | — | 4/8/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 24,785 | — | 4/8/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 4,130,846 | — | 4/8/2024 | View on chart |
| RNAC | ▲ Buy | Option Exercise | 1,970,443 | $2.9M | 3/26/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 800 | $488 | 3/18/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 19,044 | $11K | 3/18/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 1,200 | $672 | 3/15/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 537,500 | $315K | 3/15/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 648,372 | $352K | 3/14/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 2,000 | $1K | 3/14/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 3,200 | $2K | 3/13/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 1,200 | $735 | 3/12/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 1,200 | $785 | 3/11/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 4,800 | $3K | 3/8/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 2,400 | $2K | 2/7/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 800 | $520 | 2/6/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 800 | $552 | 1/17/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 178,000 | $0 | 1/2/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 123,925 | $50.0M | 11/15/2023 | View on chart |
| RNAC | ▲ Buy | Grant | 24,785 | $10.0M | 11/15/2023 | View on chart |
| RNAC | ▲ Buy | Open Market | 6,681,600 | — | 4/11/2022 | View on chart |
| RNAC | ▲ Buy | Open Market | 211,190 | $631K | 12/15/2021 | View on chart |
| RNAC | ▲ Buy | Open Market | 14,592 | $43K | 12/13/2021 | View on chart |
| RNAC | ▲ Buy | Open Market | 58,681 | $175K | 12/10/2021 | View on chart |
| RNAC | ▲ Buy | Open Market | 3,748,000 | $11.5M | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.